Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation

Metabolic syndrome (MetS) is a complex medical disorder characterized by insulin resistance, hypertension, and high risk of coronary disease and stroke. Microvascular rarefaction and endothelial dysfunction have also been linked with MetS, and recent evidence from clinical studies supports the effic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular biology reports 2014-08, Vol.41 (8), p.4853-4863
Hauptverfasser:	Amber, Cicek Figen, Zeynep, Tokcaer-Keskin, Evren, Ozcinar, Yusuf, Bozkus, Can, Akcali Kamil, Belma, Turan
Format:	Artikel
Sprache:	eng
Schlagworte:	acute effects Analysis of Variance Animal Anatomy Animal Biochemistry Animals aorta Aorta - drug effects Aorta - pathology Apoptosis Biomedical and Life Sciences Blotting, Western clinical trials coronary disease diabetes Dipeptidyl-Peptidase IV Inhibitors - pharmacology endothelial cells Epigenesis, Genetic - drug effects Epigenetics Fluorescent Antibody Technique glycemic control Histology Histones - drug effects Hyperglycemia hypertension insulin resistance Life Sciences Metabolic syndrome Metabolic Syndrome - chemically induced Metabolic Syndrome - drug therapy Molecular biology Morphology nitric oxide patients phosphorylation post-translational modification protein kinases Pyrazines - pharmacology Rats receptors risk Sitagliptin Phosphate stroke Sucrose - administration & dosage Sucrose - adverse effects Triazoles - pharmacology Vasodilation - drug effects Vasodilation - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!